SHINE Technologies has raised $240M to expand its nuclear medicine operations, including large-scale production of Lutetium-177 used in targeted cancer therapies, following its recent acquisition of Lantheus’ SPECT business...
SHINE Technologies has completed the acquisition of the Lantheus SPECT portfolio and manufacturing facility while naming Michael Rossi as CEO of the new SHINE SPECT division...
Published by Nucleation Capital in Advanced Nuclear, Company Milestone, Fusion, Medical Isotopes, NEWS, Nuclear innovation, Nuclear R&D, Portfolio Venture, US competitiveness, Venture capital support for nuclear
Sign up to receive Nucleation Insights
For New Investors
For Donors & Advocates
For Current Investors
(Note: Must be logged in at AngelList)
Nucleation Direct Messages
Nucleation (Fund I) Posts
Your Portfolio Dashboard
Your Funding Page
How to Contact Us
© 2026 Nucleation Capital | Terms & Policies
